Day: February 5, 2025

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Oppenheimer’s 35th Annual Healthcare Life Sciences Conference – Fireside ChatDate: Wednesday, February 12, 2025Time: 2:00 p.m. – 2:30 p.m. ETLocation: Virtual B. Riley Securities Precision Oncology & Radiopharma Investor Conference Date: Friday, February 28, 2025Location: New York, NY Webcast events can be accessed live, and replays will be archived for 90 days and available...

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also host one-on-one meetings with investors during these events. Oppenheimer Annual Healthcare Life Sciences Conference 2025Format: PresentationDate: Tuesday, February 11, 2025, at 9:20 a.m. ETWebcast link: https://wsw.com/webcast/oppenheimer39/mdna/2754560 Webcast and replay information for this event will be available on the investor relations section of Medicenna’s website on the Events & Presentations page....

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSX‐V: VO; OTCQB: KVLQF; Frankfurt: KEQ0) today provided an update on developments concerning Hatchet Uranium Corp. (“Hatchet”), in which ValOre currently holds an approximate 56.8% ownership interest. Hatchet entered into agreements (the “Transactions”) with Skyharbour Resources Ltd. (“Skyharbour”), (CLICK HERE for ValOre news release on November 4, 2024), whereby Hatchet could acquire an 80% interest in Skyharbour’s 9,339 hectare (ha) Highway Uranium Property and a 100% interest, subject to a “claw-back” provision for Skyharbour, in Skyharbour’s Genie, Usam and CBX/Shoe Uranium Projects totalling 66,358 ha, all located peripheral to the Athabasca Basin, in northern Saskatchewan, Canada. As part of the Transactions, Hatchet was required...

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is providing an update on the progress of the Premier Gold Project following an initial review conducted by President and Chief Executive Officer Jim Currie and his management team. Due to the limited availability of trained labour, underground development has commenced later than expected, with slower advancement than anticipated. As a result, the previously outlined timeline for the re-start of mill operations is no longer achievable. The Company now projects ore throughput to commence in July 2025. A revised schedule and budget are currently being finalized to reflect this updated timeline. Mr. Currie commented: “Following my initial review, the mill and deposit are both expected to perform in...

Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City. Presentation Details:Event: BIO CEO & Investor Conference 2025 Date & Time: February 10, 2025, at 3:45 pm EST Location: New York Marriott Marquis, New York City Presenter: Motti Farbstein, Chief Executive & Chief Financial OfficerDuring the conference, Can-Fite’s management team will engage in one-on-one meetings with investors and potential partners to discuss the company’s business strategy, recent clinical milestones, and upcoming...

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications. AGN Neuro is also pleased to announce that as part of being appointed the CRO, Validcare has agreed to invest US $170K in exchange for equity...

Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited (“Jefferies”) as its Joint Corporate Broker and Joint Financial Adviser, to work alongside RBC Capital Markets, with immediate effect. -Ends- Enquiries:         OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB...

BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) — Plymouth Industrial REIT, Inc. (NYSE: PLYM) announced the sale of a 33,688-square-foot flex building in Memphis, TN to an end user at a price of $2.4 million. The building was part of a portfolio Plymouth acquired in July 2024 for $100.5 million. At the time of acquisition, Plymouth targeted this building for divesture as it represented a non-core asset leased on a short-term basis to a tenant known to be vacating at its scheduled lease expiration in December 2024. The sale proceeds will be retained within the portfolio to fund leasing activities and the ongoing conversion of a 100,000-square-foot call center building back to its original warehouse format to accommodate multiple industrial users. Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, “This is another...

Dayforce® recurring revenue of $347.9 million, up 19% year-over-year in the fourth quarter Total revenue of $465.2 million, up 16% year-over-year in the fourth quarter Full year 2024 net cash provided by operating activities of $281.1 million, up 28% Annual Dayforce gross revenue retention rate of 98% MINNEAPOLIS and TORONTO, Feb. 05, 2025 (GLOBE NEWSWIRE) — Dayforce, Inc. (“Dayforce” or the “Company”) (NYSE:DAY) (TSX:DAY), a global leader in human capital management (“HCM”) technology, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. “2024 was a year of outstanding progress and innovation for Dayforce. We launched the Dayforce brand, maintained our product positioning as leaders in HCM, and drove significant innovation to help our customers...

TORONTO, Feb. 05, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA) announces that the Company has acquired an additional 3.46 bitcoin for CAD$500,000 (USD$344,257). The 3.46 bitcoin was acquired at an average price of USD$99,580 per bitcoin, inclusive of fees and expenses. This acquisition brings Matador’s Bitcoin holdings to approximately 68.14 bitcoin (and Bitcoin equivalents), reinforcing its long-term capital preservation strategy. The Company continues to operate debt-free, with all Bitcoin (and Bitcoin equivalent) holdings free and clear. The Company also maintains cash reserves of approximately CAD$1.8 million and physical gold holdings of 2 kilograms (approximately CAD$287,000), reflecting prudent financial management aimed at sustaining long-term growth and stability. Matador...